NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors.

NG-641 - PsiOxus

Opdivo (nivolumab) - Ono Pharma, BMS

enadenotucirev (ColoAd1) - PsiOxus, BMS

Thomas Lillie; Eileen E. Parkes; Christian Ottensmeier; David Krige; Behnaz Ravanfar; Vladimir Evilevitch; Matthew Thomas; Lee S. Rosen

Apr 28, 2022